- Conditions
- Diagnosis of Melanoma
- Interventions
- Autonomic Function Tests, supine and standing catecholamines
- Behavioral · Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 2,738
matching trials from the live ClinicalTrials.gov search.
- Conditions
- BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8, Intracranial Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Refractory Melanoma
- Interventions
- Atezolizumab, Bevacizumab, Cobimetinib, Quality-of-Life Assessment
- Drug · Biological · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Uveal Neoplasms, Melanoma, Uveal
- Interventions
- Tumor Infiltrating Lymphocytes (TIL)
- Biological
- Lead sponsor
- Udai Kammula
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Neoplasms
- Interventions
- TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 64
- States / cities
- Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more
- Conditions
- Carcinoid, Neuroendocrine Tumors
- Interventions
- EPO906 epothilone B
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Iowa City, Iowa • New Orleans, Louisiana + 2 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
- Interventions
- RP1, nivolumab
- Biological
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more
- Conditions
- Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer
- Interventions
- TTI-101
- Drug
- Lead sponsor
- Tvardi Therapeutics, Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 2
- States / cities
- Houston, Texas • San Antonio, Texas
- Conditions
- Colorectal Cancer (CRC), Endometrial Cancer, Melanoma, Head and Neck Cancer, Lung Cancer, MMR-deficient Tumors, Breast Cancer, Pancreatic Cancer, Renal Cell Carcinoma (RCC), Solid Tumors, UC (Urothelial Cancer)
- Interventions
- Pembrolizumab, itacitinib, INCB050465
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 17
- States / cities
- San Francisco, California • Santa Monica, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Neuroma, Acoustic
- Interventions
- Microsurgery, Stereotactic radiation therapy
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2022
- U.S. locations
- 9
- States / cities
- Stanford, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more
- Conditions
- Vestibular Neuronitis, Vestibular Neuronitis, Bilateral, Vestibular Schwannoma
- Interventions
- Control exercises, gaze stabilization exercises
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Transitional Cell Carinoma of Bladder, Colorectal Cancer
- Interventions
- AMG 228
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- La Jolla, California • New Haven, Connecticut • New York, New York
- Conditions
- Solid Tumors With PTCH1 Loss-of-function Mutations
- Interventions
- ENV-101 (taladegib)
- Drug
- Lead sponsor
- Endeavor Biomedicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Colon, Cancer Skin, Cancer of Cervix, Cancer, Metastatic, Cancer of Larynx, Cancer of Neck, Cancer of Lung, Cancer of Brain and Nervous System, Cancer of Vulva, Disseminated, Cancer of Pancreas, Sarcoma, GIST, Small-cell Lung Cancer, Adenocarcinoma Lung, Cancer of Prostate, Cancer, Advanced, Adrenal Cancer, Testicular Cancer, Uterine Cancer, Bronchoalveolar Cell Lung Cancer, Cancer Unknown Primary, Glioblastoma Multiforme, Oligodendroglioma, Breast Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Cancer, Other, Cancer, Anal, Melanoma, Cancer, Bile Duct, Cancer, Bladder, Cancer Cords Vocal, Cancers Cell Neuroendocrine, Cancer Differentiated Poorly, Cancer, Anaplastic Thyroid
- Interventions
- Not listed
- Lead sponsor
- SpeciCare
- Industry
- Eligibility
- 1 Month to 99 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Gainesville, Georgia
- Conditions
- Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Regional Adrenal Gland Pheochromocytoma, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma
- Interventions
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Questionnaire Administration
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma
- Interventions
- Vemurafenib, Metformin
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Advanced Neuroendocrine Tumors of Pancreatic Origin
- Interventions
- Everolimus, Everolimus Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 24
- States / cities
- Mobile, Alabama • Anaheim, California • Los Angeles, California + 20 more
- Conditions
- Melanoma, Malignant Melanoma
- Interventions
- lovastatin, interferon alfa-2b
- Drug
- Lead sponsor
- NeoPlas Innovation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer, Lung Cancer, Melanoma, Ovarian, NSCLC
- Interventions
- SI-B036
- Drug
- Lead sponsor
- SystImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Orlando, Florida • Sarasota, Florida + 4 more
- Conditions
- Melanoma, Cutaneous Malignant
- Interventions
- IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel
- Biological · Drug
- Lead sponsor
- Immatics US, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- DFF332, RAD001, PDR001, NIR178
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Duarte, California • Boston, Massachusetts • St Louis, Missouri + 2 more
- Conditions
- Melanoma (Skin), Skin Cancer
- Interventions
- Nivolumab, Surgery to Remove Tumor for Growth of TIL, CD137, Cyclophosphamide, Fludarabine, TIL Infusion, Interleukin-2
- Drug · Procedure · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
- Interventions
- IBI363
- Drug
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 9
- States / cities
- San Francisco, California • Ocala, Florida • Plantation, Florida + 5 more
- Conditions
- Carcinoid Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Rutgers University
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Pancreatic Tumor, Benign, Pancreatic Neoplasms, Pancreatic Adenocarcinoma, Pancreatic Pseudocyst, Pancreatic Neuroendocrine Tumor, Pancreas; Insulinoma, Pancreatic Cyst, Pancreatic Teratoma, Pancreatic Polypeptide Tumor, Pancreatic Vipoma, Pancreatic Cystadenoma, Pancreas Injury, Pancreatic Gastrinoma, Pancreatic Glucagonoma
- Interventions
- Distal Pancreatectomy Sealing Using LTW
- Device
- Lead sponsor
- Laser Tissue Welding, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas